
Evolution of Phenotypic and Molecular Drug Susceptibility Testing

12

Daniela M. Cirillo, Paolo Miotto, and Enrico Tortoli

Abstract

Drug Resistant Tuberculosis (DRTB) is an emerging problem world-wide. In order to control the disease and decrease the number of cases overtime a prompt diagnosis followed by an appropriate treatment should be provided to patients. Phenotypic DST based on liquid automated culture has greatly reduced the time needed to generate reliable data but has the drawback to be expensive and prone to contamination in the absence of appropriate infrastructures. In the past 10 years molecular biology tools have been developed. Those tools target the main mutations responsible for DRTB and are now globally accessible in term of cost and infrastructures needed for the implementation. The dissemination of the Xpert MTB/rif has radically increased the capacity to perform the detection of rifampicin resistant TB cases. One of the main challenges for the large scale implementation of molecular based tests is the emergence of conflicting results between phenotypic and genotypic tests. This mines the confidence of clinicians in the molecular tests and delays the initiation of an appropriate treatment. A new technique is revolutionizing the genotypic approach to DST: the WGS by Next-Generation Sequencing technologies. This methodology promises to become the solution for a rapid access to universal DST, able indeed to overcome the limitations of the current phenotypic and genotypic assays. Today the use of the generated information is still challenging in decentralized facilities due to the lack of automation for sample processing and standardization in the analysis.

D.M. Cirillo (✉) • P. Miotto • E. Tortoli
IRCCS San Raffaele Scientific Institute, Milan, Italy
e-mail: cirillo.daniela@hsr.it; miotto.paolo@hsr.it;
tortoli.enrico@hsr.it

© Springer International Publishing AG 2017

S. Gagneux (ed.), *Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control*, Advances in Experimental Medicine and Biology 1019, DOI 10.1007/978-3-319-64371-7_12

221

The growing knowledge of the molecular mechanisms at the basis of drug resistance and the introduction of high-performing user-friendly tools at peripheral level should allow the very much needed accurate diagnosis of DRTB in the near future.

Keywords

Molecular drug susceptibility test • Phenotypic drug susceptibility test

12.1 Introduction

Proper managing of tuberculosis requires starting an effective antitubercular therapy as soon as possible to prevent spreading of the disease and to increase the cure rate of the affected individuals (Uys et al. 2009; Dowdy et al. 2008). Appropriate therapy can only be provided if the drug susceptibility pattern of the infecting strain is known. Drug susceptibility testing (DST) for *M. tuberculosis* can be performed by conventional phenotypic methods or by molecular detection of genetic determinants associated with drug resistance. The two approaches have advantages and disadvantages and in the most difficult cases a combination of the two may be required. Conventional DST based on mycobacterial growth on both solid and liquid media is time-consuming, and challenged by technical difficulties and biosafety issues (Kim 2005; WHO 2012a, b; Jiang et al. 2013; Somoskovi and Salfinger 2015). The development of molecular technologies has led to the emergence of rapid diagnostic assays suitable for the detection of drug-resistant tuberculosis. Despite these advancements in technology and the large amount of data that are going to be collected by Whole Genome Sequencing (WGS) of drug resistant and drug sensitive *M. tuberculosis* strains, we cannot abandon completely phenotypic DST at this time. Achieving a more comprehensive understanding of the genotype-phenotype-clinical outcome associations could lead to a future when molecular DST will become the routine and phenotypic will be restricted as a referral test for few cases.

We can predict that deeper knowledge will be available in the near future allowing designing

a full molecular DST for routine testing. Phenotypic tests and Minimal Inhibitory Concentration (MIC) will be reserved for the most challenging cases.

12.2 Phenotypic DST

Streptomycin, the first antituberculosis drug was first experimented in 1944 (Jones et al. 1944; Emmart 1945; Smith and Waskman 1947). Shortly after its introduction in clinical practice, the first cases of resistance were reported (Youmans et al. 1946). Not substantially different was the history of all other antimycobacterial agents; resistance was rapidly emerging in particular when drugs were used inappropriately or in monotherapy (Guernsey and Alexander 1978; Smith et al. 2013). It became clear that a combination of several effective drugs was essential to achieve cured in patients with tuberculosis. The need to develop a laboratory test able to predict antibacterial sensitivity to a specific drug soon emerged and in the 1960s the pioneering experiments of Canetti, at the Pasteur Institute of Paris, led to the development of the “Proportion method” (Canetti et al. 1963). It is based on the empiric observation that when the proportion of resistant mutants within the *M. tuberculosis* population infecting the patient is approximately $\geq 1\%$, the probability of treatment failure is very high. The proportion method uses a set of media, each containing the “critical” concentration of a single drug, to test the growth of the strain in comparison with that obtained on a drug-free medium (the growth control). The susceptibility to single antimicrobials is inferred by determining the percentage between the counts of colonies grown on

the medium with the drug and on the control; whenever this proportion is $\geq 1\%$ the strain is classified as resistant. Several years earlier the same researcher had developed the “Absolute Concentration” method (Canetti et al. 1969), a kind of MIC determination with multiple drug concentrations; in this case each laboratory was requested to define its critical concentration. The Resistance Ratio method relies, for each determination, on a parallel testing of the susceptible reference strain *M. tuberculosis* H37Rv (Kent and Kubica 1985). The results are interpreted on the basis of the ratio between the MICs of reference and test strains. The proportion method, thanks to its easy implementation and interpretation, rapidly prevailed and its principle is still at the basis of modern phenotypic susceptibility testing for *M. tuberculosis*. A feature shared by all methods on solid media is the long incubation time which, added to the time for culture, make results available for clinical use in not less than 2–3 months.

In the last 40 years the liquid media, suitable to shorten the incubation time, have progressively replaced the classical solid media for the culture of *M. tuberculosis*.

At present the commercial Mycobacteria Growth Indicator Tube (MGIT) 960 system (Becton Dickinson) has monopolized the market worldwide. It is an automated system that infers the bacterial growth rate from the oxygen consumption. When used for the determination of antimicrobial susceptibility a set of tubes of liquid medium, added with critical concentrations of drugs, is inoculated with a standardized suspension of the strain to be tested; while the control tube is inoculated with the standardized suspension above, diluted 1/100. The tubes, with and without drug, are monitored in parallel and the software, upon quality validation, reports susceptibility or resistance on the basis of the comparison of respective growth curves (Rüsch-Gerdes et al. 1999; Tortoli et al. 2002).

Although the MGIT is widespread, it is not the only method available. The classical proportion methods on egg-based solid media, along with its variant on agar media (Middlebrook 7H10

or Middlebrook 7H11), are still considered the reference for several antibiotics.

Micro-dilution methods in liquid medium have also been developed which, combining inexpensiveness and ease reading, are especially suited for low-income countries. In the Microscopic Observation Drugs Susceptibility (MODS) assay the drug resistance is detected by the low magnification observation of the growth in liquid medium dispensed in micro-wells and added with drugs. The reading is made easy by the characteristic corded morphology of *M. tuberculosis* colonies (Moore et al. 2004). In another microtiter assay, the addition of a redox indicator is used to detect the bacterial growth (TeMA, MABA, ReMA, according to the indicator used: tetrazolium, alamar blue, resazurin). The color change due to indicator reduction is consistent with bacterial growth and indicates resistance to the antimicrobial present in the micro-well (Collins and Franzblau 1997).

Differently from MODS and other microtitre assays, which are home-made, a microdilution method based on microtitre plates containing twofold concentrations of freeze-dried drugs has been recently commercialized. This method, still under validation, combines a number of potential benefits: the inclusion in a single test of both first- and second-line drugs, the possibility of MIC determination, it is user-friendly and relatively inexpensive (Hall et al. 2012).

First-line drugs (isoniazid, rifampicin, pyrazinamide and rifampicin) are normally tested with the phenotypic approach; in case of simultaneous isoniazid- and rifampicin-resistance the test must be widened to second line molecules, at least to fluoroquinolones and injectables (amikacin, kanamycin and capreomycin).

In general, the phenotypic susceptibility testing produces reliable results, in particular for the two major antitubercular drugs, rifampicin and isoniazid. For ethambutol, a bacteriostatic drug, the results are less reliable (Madison et al. 2002) and DST for this drug is not considered a priority by the World Health Organization (WHO). Pyrazinamide testing has been reported as highly challenging by several laboratories, and results may not be fully reliable (Piersimoni et al. 2013).

Pyrazinamide is a prodrug and needs a low pH for activation, a condition that is difficult to control in an “in vitro” test (Table 12.1).

Critical Concentrations (CC) for the major antitubercular drugs were proposed by WHO in 2008, revised in 2012 and under revision in 2017. Table 12.2 shows the critical concentrations endorsed by WHO in 2012. Drugs used for treatment of rifampicin resistant tuberculosis and MDR tuberculosis are listed according to the new classification published in 2016 in the last WHO manual for drug resistant tuberculosis (<http://www.who.int/tb/areas-of-work/drug-resistant-tb/MDRTBguidelines2016.pdf>). It must be noted that some of the CCs will be revised very soon as reported in the table legend.

CCs should be established at the epidemiological cut-off value (ECOFF) or one dilution higher. For the majority of the drugs, the ECOFF separates wild-type strains expected to be sensitive from those expected to be resistant to a selected drug. If drugs can be used at higher doses without high risk of toxicity, concentration higher than the CC can be tested to predict sensitivity to treatment when high doses of the drug can be used to achieve higher plasmatic concentration. In this case a “clinical breakpoint” can be established; for example, a clinical breakpoint has been recently established for moxifloxacin. For some drugs, CCs cannot be established due to the lack of data. For drugs such cycloserin, imipenem, amoxi/clavulanate *in vitro* testing is still not recommended due to the absence of reliable protocols.

As a general rule, it is advisable to test the drug in use for treatment and to perform susceptibility tests under quality assurance conditions and strictly adhering to the recommended protocols.

Recently, two new drugs, delamanid and bedaquiline, received conditional approval for treatment of MDR-TB cases. Interim CCs were recently discussed and will be reported officially by WHO at the end of 2017. Protocols for susceptibility testing on liquid and solid media have been published (Schena et al. 2016; Torrea et al. 2015).

Interpretation of discrepant results obtained in different high level laboratories, from phenotypic tests performed on different media or between genotype and phenotype has underlined the need of MIC determination for a correct management of difficult cases.

Plates for MIC determination are commercially available but have been only evaluated on a small scale so far (Hall et al. 2012). These microtitre plates allow the MIC determination for several first and second line antimycobacterial agents. Yu et al. (2016) have recently reported an agreement between plates and LJ of 99.2% for rifampicin, ofloxacin, amikacin, kanamycin and cycloserin, 98.4% for isoniazid and PAS and lower than 90% for ethambutol. The use of microtitre plates highly reduces the cost of DST compared to other liquid media but poses several questions on the feasibility in terms of implementation in laboratories located in high burden countries for the level of biosafety requested to handle the plates and the risk of cross-contamination. Automation in plate-reading and a “sealed” layout could improve the use of MIC plates in the future.

Although all the methods in liquid medium have drastically reduced the turnaround time, the cost of maintaining an adequate level of bio containment and the high rates of contaminated culture remain a major limit to implement phenotypic DST in TB high burden settings.

12.3 Molecular DST

12.3.1 Molecular Basis of Drug Resistance in *M. tuberculosis*

In *M. tuberculosis*, drug resistance is mainly caused by chromosomal mutations and evidences exclude horizontal transfer of genetic material as a source of resistance (Gillespie 2002; Marttila and Soini 2003). In a limited number of cases, mobile genetic elements (such as insertion sequences, *e.g.* IS6110 see Chap. 3) can contribute to the insurgence of phenotypic drug resistance (Lemaitre et al. 1999).

Table 12.1 (continued)

Drug Groups ^a	Drug	DST method available	DST critical concentration ($\mu\text{g/ml}$)		
			Löwenstein-Jensen ^b	Middlebrook 7H10 ^b	Middlebrook 7H11 ^b MGIT960
Add-on agents (D) (not part of the core MDR-TB regimen)	D1 First-line oral anti-TB agents (Pyrazinamide, Ethambutol, Isoniazid HD)				
	D2 Bedaquiline ^l	Solid, liquid	-	-	-
	Delamanid ^m	Solid, liquid	-	-	-
	D3 P-aminosalicylic acid	Solid, liquid	1.0	2.0	8.0
	Imepenen-cilastatin	None	-	-	-
	Meropenem	None	-	-	-
	Amoxicillin/clavulanate (Thioacetazone)	None	-	-	-

In bold the CC that will be updated in 2017

^aModified according to WHO Guidelines for the programmatic management of drug-resistant tuberculosis

^bIndirect proportion method recommended. Other solid media methods (resistance ratio) have not been adequately validated for second-line drugs. Concentrations for the absolute concentration method were not evaluated

^cEthambutol 5 $\mu\text{g/ml}$ in MGIT is not equivalent to other methods. Ethambutol testing in 7H11 not equivalent to 7H10

^dRifampicin borderline resistance can be missed by MGIT and can cause discrepant phenotypic/genotypic results

^eAmikacin. Critical concentration on 7H10 it is expected to be decreased

^fGatifloxacin the drug is not widely available. Few data are available to establish the CC

^gMoxifloxacin. Two concentrations were proposed in 2012. Testing for moxifloxacin at 2 mg/L underestimate resistance and truncates the distribution of mutant strains. It is anticipated that new recommendations will decrease the CC for moxifloxacin and levofloxacin in order to reflect the distribution of wild type and mutated strains. A clinical breakpoint for moxifloxacin is under discussion

^hOfloxacin is not used for therapy, it is suggested to use the fluoroquinolone included in regimens

ⁱClofazimine provisional CC for MGIT will be proposed in 2017

^jCycloserine. Critical concentration in LJ will be withdrawn due to concerns of unreliable testing and reproducibility

^kLinezolid tentative CC, CC on solid media will be proposed in 2017

^lBedaquiline CC will be proposed in 2017

^mDelamanid CC will be proposed in 2017

Table 12.2 Main genomic regions associated with drug resistance in *M. tuberculosis*

Drug	Gene(s) containing drug resistance-conferring mutations
Amikacin	<i>rrs</i>
Bedaquiline	<i>mmpL5, mmpS5, Rv0678, atpE, pepQ</i>
Capreomycin	<i>rrs, tlyA</i>
Clofazimine	<i>Rv0678, pepQ</i>
Delamanid	<i>ddn, fgd1, fbiA, fbiB and fbiC</i>
Ethambutol	<i>embA, embB, embC, ubiA</i>
Ethionamide	<i>inhA, ndh, ethA, ethR</i>
Fluoroquinolones	<i>gyrA, gyrB</i>
Isoniazid	<i>katG, inhA, ndh, furA, kasA</i>
Kanamycin	<i>rrs, gidB, eis, tap, whiB7</i>
Linezolid	<i>rplC, rrl</i>
Pyrazinamide	<i>pncA, rpsA, panD</i>
Rifampicin	<i>rpoB</i>
Streptomycin	<i>rpsL, rrs, gidB, tap, whiB7</i>

Drug resistance can be defined according to different criteria. Clinical resistance is based on breakpoints determining the likelihood of therapeutic failure during treatment. Even though this definition is useful for clinical practice, it does not consider low-level resistance mechanisms that increase the MIC without reaching the breakpoint, thus representing an hallmark of a possible evolutionary trend towards high-level (clinically relevant) resistance (Baquero 2001; Martínez et al. 2015). Alternatively, resistance could be referred according to an epidemiological definition: the European Committee on Antimicrobial Susceptibility Testing (EUCAST) established common ECOFFs defined as the MIC value corresponding to the upper limit of the wild-type population of a specific bacterial species (Kronvall 2010). In this case, low-level resistance can be also determined. Table 12.2 summarizes main genomic regions involved in the emergence of drug resistance to preeminent anti-tubercular drugs (see Chap. 14).

Rifampicin is an excellent example for molecular evaluation of phenotypic resistance: more than 95% of the mutations causing drug resistance are mapping in a short (81 nucleotides in length) “hot-spot” region in the *rpoB* gene (Ramaswamy and Musser 1998). Despite the variability of mutations found, four mutations

(D516V, H526Y, H526D, and S531L – refer to Andre 2016 for corresponding *M. tuberculosis* codon numbering system (Andre et al. 2016)) account for more than 70% of resistant clinical isolates. Different mutations can also be associated to different fitness (Comas et al. 2011; Brandis et al. 2012; de Vos et al. 2013). Due to the lower rate of spontaneous mutations, rifampicin resistance alone is rarely observed, and the majority of rifampicin-resistant isolates have already accumulated mutations conferring resistance to isoniazid (Coker 2004). This observation initially leads policy-makers to consider rifampicin-resistance as a marker for MDR tuberculosis. However, further data showed that rifampicin resistance is not a good surrogate marker at the global level for MDR-TB and its reliability is strictly dependent on the rate of primary resistance to rifampicin in the setting considered (WHO 2004).

Isoniazid resistance is caused by mutations affecting different genomic regions: approximately 60% and 20% of resistant cases are caused respectively by mutations affecting the codon 315 in the *katG* gene and the position –15 in the *inhA* gene promoter region (Seifert et al. 2015). Different mutations in these regions slightly increase the percentage of isolates with at least one reported mutation. The mutation frequency was

also found to be different according to the geographical distribution (Seifert et al. 2015). Other genomic regions involved in isoniazid resistance are in the *ndh*, *furA* and *kasA* genes, however their contribution is usually below 1% (Banerjee et al. 1994; Kelley et al. 1997; Sreevatsan et al. 1997; Banerjee et al. 1998; Slayden and Barry 2000; Lee et al. 2001; van Doorn et al. 2003; Vilchèze et al. 2005). Recently, another potential target of the drug has been proposed: the MymA protein, a flavin-containing monooxygenase was found to be inhibited by isoniazid in modeling and biochemical analyses (Saraav et al. 2017). Further studies will help in understanding any role of this putative target in the development of isoniazid resistance. Other studies focusing on bacterial persistence underlined the complexity of the interaction between antibiotics and bacteria. In particular, studies on isoniazid showed that single-cell dynamics of the isoniazid-activating enzyme catalase-peroxidase (KatG) are driving the success of the drug; thus, persistence to isoniazid was likely due to reversible phenotypic tolerance rather than stable genetic mutations (Wakamoto et al. 2013). Several mechanisms of bacterial persistence have been described, and many were also found in *M. tuberculosis* (Nathan 2012; Dartois et al. 2016; Harms et al. 2016).

Ethambutol resistance is caused by mutations affecting the *embCAB* operon, and the *emrB* gene encoding for its regulator (Telenti et al. 1997). Most frequent mutations are observed at codon 306 of the *emrB* gene (approximately 70% of resistant cases) (Zhang and Yew 2015). Recently, mutations affecting the *ubiA* gene have also been associated with ethambutol resistance (Safi et al. 2013; He et al. 2015). Researchers started to characterize the frequency of mutations at this locus in clinical isolates. However, they seem associated to particular geographical regions (Xu et al. 2015; Lingaraju et al. 2016).

Pyrazinamide resistance is caused by mutations affecting the *pncA* gene encoding the pyrazinamidase enzyme required to convert pyrazinamide to its active form pyrazinoic acid (Zhang and Mitchison 2003). Resistance-conferring mutations are spread along the entire gene, including the promoter region, and a clear hot-spot

region cannot be identified. In addition, more than 600 different mutations (including indels) have been described in the literature, making the detection of individual mutations or a restricted subset of them useless for diagnostic purposes (Miotto et al. 2014; Ramirez-Busby and Valafar 2015; Whitfield et al. 2015). In some cases, insertion of the IS6110 mobile genetic element in the gene has been also reported (Gillespie 2002). According to the most recent systematic review available, mutations in the *pncA* locus are responsible of 83% of pyrazinamide resistant cases (Ramirez-Busby and Valafar 2015). Mutations affecting two novel genetic loci have been associated with the emergence of pyrazinamide resistance: evidences suggest that *rpsA* and *panD* genes are involved in the mechanism of action of the drug (Yang et al. 2015; Pandey et al. 2016), however only a relatively small number of clinical isolates have been characterized for these genomic regions, and the clinical relevance of these targets remains questionable. Pyrazinamide monoresistance is an extremely rare phenotype (with the exception of *M. bovis* and *M. canettii*) and any phenotypic resistance in the absence of *pncA* mutations should be interpreted with extreme caution.

Streptomycin resistance is caused by mutations in the *rpsL* gene, with codons 43 and 88 as the most affected ones. Mutations in this genetic locus account for approximately 50% of streptomycin-resistant clinical isolates. An additional 10% of resistant strains harbor mutations in regions 530 and 912 of the *rrs* gene (Sreevatsan et al. 1996). Other genes described as involved in streptomycin resistance are *gidB*, *tap* and *whiB7* genes (Okamoto et al. 2007; Wong et al. 2011; Reeves et al. 2013). Mutations in the *rrs* gene but at different region (region 1400) are also associated with resistance to amikacin, kanamycin and capreomycin (Alangaden et al. 1998; Maus et al. 2005). In addition, mutations in the promoter region of *eis* gene and in the *tlyA* gene are responsible of kanamycin and capreomycin resistance, respectively (Johansen et al. 2006; Zaunbrecher et al. 2009). According to Georghiou et al., the *rrs* 1401 mutation alone is found in 70–80% of amikacin and capreomycin

resistant isolates, and in 60% of strains resistant to kanamycin (Georghiou et al. 2012). The contribution of mutations in the promoter region of the *eis* gene to kanamycin resistance is variable across different geographical regions, however in some settings it can rise up to more than 60% of resistant cases (Hoshide et al. 2014). The contribution of mutations in *tlyA* gene in determining capreomycin resistance remains low to moderate (5–10%) (Campbell et al. 2011; Georghiou et al. 2012).

Similarly to the other anti-tubercular drugs, resistance to fluoroquinolones is promoted by sub-optimal bacterial-drug exposure (Miotto et al. 2015). Main drug resistance-associated mutations are found in the quinolone resistance determining regions (QRDRs) of the *gyrA* and *gyrB* genes. In particular, 80% of resistant cases harbor mutations in the QRDR of the *gyrA* gene, whereas mutations in the *gyrB* gene contribute for less than 1% of resistant cases (Avalos et al. 2015). Several studies showed that the levels of resistance to the different fluoroquinolones (namely levofloxacin, ciprofloxacin, ofloxacin, moxifloxacin, gatifloxacin) are associated with the type of mutation present in the *gyrA* and *gyrB* genes, however MIC values for isolates with the same mutation vary widely (Kam et al. 2006; Nosova et al. 2013; Kambli et al. 2015; Chien et al. 2016; Farhat et al. 2016a, b). Concordance in resistance testing among fluoroquinolones was found to be low (Farhat et al. 2015; Coeck et al. 2016). These observations lead to consider the possibility to use later-generation fluoroquinolones (moxifloxacin, gatifloxacin) to treat cases resistant to earlier generation (levofloxacin, ciprofloxacin, ofloxacin) fluoroquinolones (resistance detected by phenotypic tests using CC published in 2012). According to Farhat et al. (2015), nearly 30% of strains had moxifloxacin MICs in the intermediate range, likely below the peak serum concentrations of the drug, and thus clinically treatable with standard doses of moxifloxacin (despite distribution of drugs in the granulomas could not reflect the serum level of the antibiotic, as suggested by Dartois and Barry 2013). Similarly, a previous study described ofloxacin-resistant

cases showing improved treatment outcomes when treated with moxifloxacin (Jo et al. 2014). Van Deun et al. suggested that specific *gyrA* gene mutations can be used to predict poor treatment outcome in MDR tuberculosis, and in particular mutations other than Ala substitution at codon 94 are associated with high-level resistance to gatifloxacin and moxifloxacin (Rigouts et al. 2016).

Data for drugs recently introduced in the treatment of MDR and XDR tuberculosis such as linezolid, delamanid, bedaquiline and clofazimine are scarce, both in terms of genetic loci involved and prevalence (Bloemberg 2015; Xu 2017). Further work is needed to fill present knowledge gaps. Resistance to linezolid is mainly caused by mutations in *rplC* and *rrl* genes (Hillemann et al. 2008; Beckert et al. 2012; Makafe et al. 2016), whereas resistance to delamanid is mediated by mutations affecting *ddn*, *fgd1*, *fbiA*, *fbiB* and *fbiC* genes (Stover et al. 2000; Choi et al. 2001; Matsumoto et al. 2006; Manjunatha et al. 2006; Feuerriegel et al. 2011). Resistance to delamanid has been observed in strains never exposed to the drug and presenting mutations in *ddn* (Skena et al. 2016). Mutations affecting *mmpL5*, *mmpS5*, *pepQ*, *Rv0678*, *atpE* genes cause resistant to bedaquiline (Andries et al. 2005; Huitric et al. 2010; Andries et al. 2014; Hartkoorn et al. 2014; Almeida et al. 2016; Segala 2012). Mutations in *Rv0678* and *pepQ* were found to confer cross-resistance between bedaquiline and clofazimine, an antileprosy drug recently gaining attention for treating MDR tuberculosis (Hartkoorn et al. 2014; Almeida et al. 2016). In particular, mutations in *Tv0678* were linked to the upregulation of *mmpS5* and *mmpL5* genes. Resistance mediated by *pepQ* mutation seems to be associated with increased drug efflux, but this is not due to upregulation of *mmpL5* and *mmpS5* expression as in the case of resistance mediated by mutations in the *Rv0678* gene.

The frequency of mutations in these genomic regions remain to be determined in clinical isolates and only limited data on small number of samples are available.

The mycobacterial cell wall permeability barrier and active multidrug efflux pumps represent

a relevant role in the development of phenotypic drug resistance in *M. tuberculosis* (De Rossi et al. 2006; Escribano et al. 2007; Louw et al. 2009; da Silva et al. 2011). Studying these specific aspects of the biology of *M. tuberculosis* requires more sophisticated experiments and the identification of mutations related to these mechanisms is more complex; therefore, there are very limited data available on clinical isolates covering these mechanisms of resistance (see Chap. 14).

For drugs sharing the same molecular target cross-resistance is commonly observed. This phenomenon has been reported for fluoroquinolones, second-line injectable drugs, but also for isoniazid and ethionamide. However, it should be noted that certain mutations confer different level and pattern of resistance among the different drugs. Table 12.3 summarizes some of the main information available on cross-resistance and its molecular bases, together with main references.

12.3.2 Molecular Identification of the Drug Susceptibility Profile of *M. tuberculosis*

The bottleneck in the molecular detection of drug resistance in *M. tuberculosis* is the limited knowledge of the relevant mutations responsi-

ble of the resistant phenotype (Zhang and Yew 2015). There are several genotypic approaches to detect known mutations causing drug resistance; the use of the polymerase chain reaction (PCR) in the diagnosis of tuberculosis was introduced in 1990 (Patel et al. 1990) and few years later, starting on 1993 (Telenti et al. 1993), PCR-based assays have been developed for the detection of drug resistance in *M. tuberculosis* (for reviews on early developed methods please refer to Caws 2001; García de Viedma 2003). Together with undeniable advantages in terms of both ease of use and reduced time-to-results, the introduction of molecular assays for direct drug susceptibility profiling of *M. tuberculosis* in specimens also reduced biosafety risks associated with the manipulation of live pathogens, especially in resource-limited settings (WHO 2008; Parsons et al. 2011; WHO 2013; Somoskovi and Salfinger 2015).

Although molecular techniques can detect a single bacillus in a specimen (at least in theory), sensitivity can be hampered by the presence of inhibitors in clinical specimens and loss of nucleic acids during specimen processing. In addition, the need to detect mutations affecting multiple genes (*e.g.* those required to identify delamanid or bedaquiline resistances) and/or the multiplicity of mutations on a single target (*e.g.* mutations in *pncA* gene associated with pyrazinamide resis-

Table 12.3 Genes involved in cross resistance to anti-TB drugs

Cross-resistances	Genomic region	Example mutations	References
Amikacin, kanamycin, capreomycin	<i>rrs</i>	a1401g, a1484t	Blumberg et al. (2003), Maus et al. (2005), and Georghiou et al. (2012)
Bedaquiline, clofazimine	<i>Rv0678</i>	S63R, R134Stop	Hartkoorn et al. 2014
	<i>pepQ</i>	A14ins c, R271del c, L44P	Almeida et al. (2016)
Ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin	<i>gyrA</i>	G88C, A90V, S91P, D94N, D94G, D94Y N538D, E540V,	Malik et al. (2012), Nosova et al. (2013), Imperiale et al. (2014), and Willby et al. (2015)
	<i>gyrB</i>	R485C + T539N	
Levofloxacin, ofloxacin	<i>gyrB</i>	D500H, D500N	Malik et al. (2012)
Isoniazid, ethionamide	<i>inhA</i>	c-15t	Imperiale et al. (2014) and Rueda et al. (2015)
Rifampicin, rifabutin	<i>rpoB</i>	Q513E, Q513K, Q513L, Q513P, S531L, S531F, S531W, H526D, H526Y, H526R, D516A + R529Q	Bodmer et al. (1995), Sintchenko et al. (1999), Goldstein (2014), Jamieson et al. (2014), Imperiale et al. (2014), and Berrada et al. (2016)

tance) considerably limit the choice to the techniques with a sufficient capacity for multiplexing.

Starting in 2008, molecular tools detecting rifampicin resistance-associated mutations have been formally endorsed by the World Health Organization, as they represent cost-effective rapid diagnostics for fast detection of resistant cases. In particular, based on evidence and expert opinion, the WHO endorsed the use of molecular line probe assays (LiPAs), and the Xpert MTB/RIF assay (Cepheid) for the rapid detection of MDR tuberculosis cases (WHO 2008, 2013; Gilpin et al. 2016).

The commercially available LiPAs are based on targeted amplification of specific regions of the *M. tuberculosis* genome followed by hybridization of the amplicons to oligo probes immobilized on nitrocellulose strips. The INNO-LiPA Rif.TB (Innogenetics) has been designed to detect rifampicin resistance alone by targeting the hot-spot region of the *rpoB* gene with five wild-type probes and four probes specific for most frequent rifampicin resistance-associated mutations (D516V, H526Y, H526D, and S531L). Reported pooled sensitivity and specificity are 97% (95% CI 95.0–98.0) and 99% (95% CI 98.0–100.0), respectively (Morgan et al. 2005). The GenoType MTBDR*plus* assay by Hain Lifescience detects both rifampicin and isoniazid resistance. The test targets the hot-spot region of the *rpoB* gene with eight wild-type probes and four probes specific for most common rifampicin resistance-associated mutations (D516V, H526Y, H526D, and S531L). The detection of isoniazid resistance is enabled by one wild-type probe plus two mutated probes for the *katG* gene (S315T, nucleotidic substitutions *agc/acc* and *agc/aca*) and two wild-type probes plus four mutated probes for the promoter region of the *inhA* gene (c-15t, a-16g, t-8c, and t-8a). The pooled sensitivity for the detection of rifampicin resistance was reported 98.1% (95% CI 95.9–99.1), with a specificity of 98.7% (95% CI 97.3–99.4). Results for isoniazid showed lower sensitivity (84.3%, 95% CI 76.6–89.8) but high specificity (99.5%, 95% CI 97.5–99.9) (Ling et al. 2008). More recently a non-inferiority study of the new version of the GenoType MTBDR*plus* assay (version

2) and a newly developed LiPA assay named Nipro NTM + MTBDRTB assay (Nipro Corporation) was published. Both tests have been designed to detect rifampicin and isoniazid resistance. The GenoType MTBDR*plus* assay ver. 2 targets the regions already described for the MTBDR*plus* ver.1 assay. Similarly, the Nipro assay targets the hot-spot region of the *rpoB* gene for rifampicin resistance (5 wild-type probes plus four mutated probes targeting D516V, H526Y, H526D, and S531L substitutions), whereas for isoniazid resistance the assay targets four wild-type probes plus two mutated probes for the *katG* gene (S315T, and S315N) and one wild-type probe plus four mutated probes for the promoter region of the *inhA* gene (c-15t, a-16g, t-8c, and t-8a). Non-inferiority of MTBDR*plus* ver.2 and Nipro assays to MTBDR*plus* ver.1 was demonstrated for rifampicin and isoniazid resistance detection (Nathavitharana et al. 2016).

The GenoType MTBDR*sl* (Hain Lifescience) is the only molecular test designed for the detection of resistance to second-line drugs. The assay targets the QRDR of the *gyrA* gene (three wild-type probes plus six mutated probes targeting mutations A90V, S91P, D94A, D94N/Y, D94G, and D94H) and the region 1400 of the *rrs* gene (two wild-type probes plus two mutated probes targeting a1401g, and g1484t). In addition, the assay targets the codon 306 of the *embB* gene for ethambutol resistance. The pooled sensitivity for detecting fluoroquinolone resistance on isolates was 83.1% (95% C.I. 78.7–86.7) and the pooled specificity was 97.7% (95% C.I. 94.3–99.1), respectively. Similar performances were found for direct testing in clinical specimens. Performance on second-line injectable drugs resistance (amikacin, kanamycin, and capreomycin) showed a pooled sensitivity of 76.9% (95% C.I. 61.1–87.6) and a pooled specificity of 99.5% (95% C.I. 97.1–99.9), respectively (Theron et al. 2014). The new version of the MTBDR*sl* assay (version 2) in addition to *gyrA* and *rrs* genes targets also the QRDR of the *gyrB* gene for fluoroquinolone resistance (one wild-type probe plus two mutated probes targeting N538D, and E540V), and the promoter region of the *eis* gene for kanamycin resistance (three wild-type probes

plus one mutated probe targeting c-14t); the target region for ethambutol has been removed. The new version of the assay showed improved performances (Tagliani et al. 2015; Brossier et al. 2016), and very recently, the WHO also provided recommendations for the use of the MTBDR_{sl} for the detection of resistance to second-line anti-tuberculosis drugs (WHO 2016).

Despite the good performances of the LiPAs on clinical isolates and smear-positive clinical specimens, it should be noted that the WHO does not recommend the use of these assays for smear-negative samples. MTBDR_{sl} assay (version 2) is recommended to triage patients for the short MDR regimen. Although not perfect, this assay can identify patients that are resistant to all second line injectable drugs (presenting the a1401g mutation in *rrs*) from those that may still respond to amikacin (position 1402, *rrs* gene). Patients presenting mutations in the promoter region of *eis* could also still be treatable with capreomycin.

At present guidelines for interpreting the genotype to predict drug responses are under preparation and more data are collected to support the interpretation of mutation pattern for clinical management of DR tuberculosis.

The Cepheid Gene Xpert MTB/RIF system is a fully automated real time PCR-based assay for the detection of *M. tuberculosis* DNA and mutations associated with rifampicin resistance, directly in clinical specimens (Boehme et al. 2010). The assay uses semi-nested PCR to amplify the hot-spot region of the *rpoB* gene (RRDR) resistance is detected by five molecular beacons targeting both wild-type sequences and the most common mutated codons. For the detection of rifampicin resistance, the pooled sensitivity and specificity were 95% and 98%, respectively (Steingart et al. 2014). Due to the high sensitivity of the assay, the Xpert MTB/RIF is also recommended for smear-negative specimens, and extra-pulmonary samples (WHO 2013; Denking et al. 2014). Despite these recommendations the sensitivity on paucibacillary samples remains suboptimal compared to liquid culture. Additional limitations for this test are the suboptimal negative predictive value (Theron et al. 2014), the capacity to detect

heteroresistance to rifampicin (Zetola 2014), low capacity to detect the C533G mutation (Rufai et al. 2014) and occasional rifampicin resistant false positive cases due to delays in the signal generated by the probes D and E (Williamson 2012) or detection of silent mutations such as F514F. A new generation of Xpert assay, named Ultra, was recently developed and evaluated in a non inferiority study including the previous version (https://www.finddx.org/wp-content/uploads/2017/03/Ultra-WHO-report_24MAR2017_FINAL.pdf). The Ultra is an improved version of the previous test (G4) working on the same platform after upgrade of software. The main differences between G4 and Ultra are: the increased volume of the PCR chamber, the target genes for detection of MTB (two multicopy genes IS6110 and IS 1081) and faster reaction kinetics. Rifampicin resistance is detected using the melting temperature curves of RRDR-specific probes. Samples are defined positive according to five semiquantitative categories. The first four (high, medium, low and very low) correspond to the G4 categories while the last one, “trace”, is new.

The Ultra cartridges have been endorsed by WHO in April 2017. In the first prospective multicenter study comparing G4 and Ultra, the Ultra showed an increased sensitivity (+17%) in smear negative respiratory samples and HIV coinfecting subjects (+14%). Specificities of Ultra and G4 for case detection were 95.6% and 98.3%, overall, and 93.5% and 98.4% among patients with a history of tuberculosis. The decreased specificity in patients with history of tuberculosis is mainly in the category of results labeled as “trace”. Samples resulting positive as “trace” will not be further analyzed for rifampicin resistance. Large amount of data will be needed to define the diagnostic value of the “trace” category. “Trace” positive subjects could be managed differently based on local TB epidemiology, patient’s history and immunological status (Chakravorty et al. 2017).

As already mentioned, the clinical value of molecular assays relies upon our knowledge of the mutations involved in the emergence of drug resistance in *M. tuberculosis*, evidences

suggest that future drug resistance diagnostics will need to be able to detect high numbers of mutations to impact on the management of patients with drug-resistance tuberculosis (Farhat et al. 2016b). However, additional considerations should be taken into account in the evaluation of such tools. First, whereas in settings with a high prevalence of rifampicin resistance and MDR-TB, these tests may be a valuable component of an MDR-TB management strategy, molecular tests for rifampicin resistance alone cannot accurately predict resistance in areas with a low prevalence of rifampicin resistance (Arentz et al. 2013; WHO 2013; Drobniewski et al. 2015). Thus, careful evaluation of the setting should be performed prior to introduction of molecular assays. Second, although some molecular tools are often easier to be performed compared to phenotypic DST, interpretation challenges may arise. Whereas rare or novel mutations usually do not account for the majority of resistance determination based on the absence of wild-type probe hybridization, continuous evaluation of geographical mutation frequencies might be needed for maximizing the impact of molecular diagnostics (Seifert et al. 2016; Sanchez-Padilla et al. 2015). Similarly, false-positive rifampicin resistance detection or detection of *M. tuberculosis* DNA by Xpert MTB/RIF assay in culture-negative patients can be confusing and detrimental for patient management (Huh et al. 2014; Lippincott et al. 2015). Third, clear data on the relationship between genotype, phenotype and response to treatment are limited. Phylogenetic polymorphisms, mutations associated with hyper-susceptibility and/or different level of resistance, and differences related to the phenotypic testing method used as reference have been described. Distinctive geographical distributions of drug resistance-associated mutations further complicate the clinical interpretation of genetic polymorphisms (Aubry et al. 2006; Rigouts et al. 2013; Feuerriegel et al. 2014; Hoshide et al. 2014; Van Deun et al. 2015; Kambli et al. 2015; Singh et al. 2015; Coeck et al. 2016; Berrada et al. 2016; Kambli et al. 2016).

Target product profiles in terms of minimal requirements, performances and controls for developing new molecular diagnostic assays for drug-resistant tuberculosis and guidelines for their successful evaluation have been developed to guide the development of new assays (Wells et al. 2013; Kik et al. 2014; WHO 2015; Denkinger et al. 2015). Currently, large efforts are devoted to fill the gaps in our understanding of the genotype-phenotype relationships. We can now take advantage from the onset of next generation sequencing (NGS). NGS is making whole genome sequencing (WGS) affordable in the broader field of microbiology (Punina et al. 2015; Gilchrist et al. 2015). Several automated or semi-automated tools for interpreting *M. tuberculosis* drug resistance in WGS data are already available (Steiner et al. 2014; Flandrois et al. 2014; Bradley et al. 2015; Feuerriegel et al. 2015; Coll et al. 2015). Recent studies highlight the need for standardized databases for interpreting genotype-phenotype correlation in clinical contexts (Witney et al. 2015). At this end, a large collaborative project involving academic institutions, public health agencies, and nongovernmental organizations has been established to develop a tuberculosis relational sequencing data platform (ReSeqTB) for improving understanding of the relationships between genotype, phenotype and clinical outcomes (Starks et al. 2015; Schito and Dolinger 2015; <https://platform.resqtb.org/>). Another consortium named “CRyPTIC” (Comprehensive Resistance Prediction for Tuberculosis, www.crypticproject.org/) aims at developing a sufficient number of sequences to unveil all possible variants leading to drug resistance.

12.4 Discrepancies Between Phenotypic and Genotypic Tests

Since the introduction of molecular tests for the diagnosis of drug resistant tuberculosis, several reports showing conflicting results were published. Discrepancies between molecular methods to detect drug resistance (including

Table 12.4 Main reasons for genotype/phenotype discrepancies

Mutation is out side the region targeted by the molecular assay
Mutation confers low level resistance and CC is set to high
Presence of unknown mechanisms conferring DR
Trivial errors in the performance of DST
Presence of heteroresistance not detected by molecular methods
Molecular assay detect silent mutations
Errors due to probe interaction/binding in LPA or other molecular assays

rifampicin resistance) and traditional phenotypic methods have caused confusion and in many settings have decreased the confidence in molecular tests. This has resulted in delay in starting treatment or inappropriate treatment when priority was given to phenotypic data. These discrepancies could be due to real “false positive” or “false negative” results of the tests used for the determination (both genotypic or phenotypic) or can be linked to more complex reasons. Table 12.4 lists the most frequent reasons for the discrepancies. As already mentioned, phenotypic tests performed on different media may yield conflicting results when the MIC of the strain for the drug tested is close to the critical concentration (Coeck et al. 2016). Technical issues related to the methodology used for DST, quality of media and drugs, experience of the staff can strongly affect the reliability of the test. Testing *M. tuberculosis* sensitivity by phenotypic methods should only be performed in laboratories maintaining a high standard in performance and with a consistent workload.

Additional causes for discrepancies are linked to the use of CCs established at value that are too high and don't represent the true distribution of the wild type and mutant bacterial population. When drugs can be used at higher doses without causing serious side effects, a clinical breakpoint can be established, and in some case it is recommended to test the drug at two concentrations. Phenotypic sensitivity at the higher concentration should not be interpreted as a “true discrepancy” but as useful information for the clinical management of the patient. Moxifloxacin is a candidate drug for testing at two concentrations.

Our knowledge on the mechanisms conferring drug resistance is still limited, and in some case determinants that are causing resistance are not properly investigated. The implementation of whole genome sequencing has highly improved our knowledge of genomic variants causing drug resistance. For some minority variants the association to drug resistance will need to be confirmed by reverse genetic experiments. Some molecular assays are not able to discriminate “silent” from “non-silent” mutations: F514F is the most common silent mutation in *rpoB*, if detected by molecular assay the sample may be misinterpreted as rifampicin-resistant.

Table 12.5 summarizes some of the most common mutations causing DR and expected phenotype.

12.5 Whole Genome Sequencing as Novel Approach to Susceptibility Testing

The whole genome sequencing (WGS) approach offers a powerful alternative for diagnosis of drug-resistant tuberculosis, promising a rapid and accurate determination of all the clinically-relevant mutations (Drobniewski et al. 2015; Witney et al. 2015; Walker et al. 2015). Indeed, using this methodology, clinicians could promptly obtain relevant information on the best therapy to adopt, receiving information on sensitivity to the first-line drugs, as well as to second-line and new agents. In addition, it is now accepted that the emergence of drug resistance is not always caused by point mutations affecting only single genes, but the presence of other mechanisms, such as compensatory mutations,

Table 12.5 Most common mutations causing DR and the expected phenotype

Antimicrobial agent	Gene	Common mutations	Less common mutations	Expected phenotype
Isoniazid	<i>katG</i>	S315T	S315T, S315N, S315I, S315L, additional mutations in <i>katG</i> coding region	S315T is the most common mutation conferring resistance to INH, is associated to medium to high level of resistance, is the most represented mutation in MDR strains
	<i>inhA</i> promoter	-15C/T	-8T/C, -8T/A, -8T/G, -9G/T, -16A/G, -17G/T	Often associated with low-level INH resistance, confers ethionamide resistance. Some strains may tests sensitive by phenotypic DST
	<i>inhA</i> coding region <i>fabG1</i>	Different codons may be affected		Mutations in the coding regions are non detected by LPA commercial assays and/or assays targeting the promoter. Presence of mutations in the coding region in association with mutations in the promoter increases the level of resistance.
	<i>ahpC</i> promoter	-48C/T	-52G/A, -54G/A, -51C/T, -52G/T, -49A/G, -57G/A	Associated with INH resistance. Few data available
Rifampin	<i>rpoB</i>	S531L	L511P, L533P, D516Y, H526N,	S531 L is the most frequent mutation identified in MDR TB, associated with resistance to all rifamicins
		H526Y	S522L, H526L, H526A, H526C, D516F, D516V	F514F is the most common silent mutation. It can cause misinterpretation of resistance to rifampicin if not recognised.
		H526D	Q513A, Q513E, H526Y, H526D, H526R, S531W, S531F, S531L, V176F.	L511P, L533P, D516Y, H526N “disputed” mutations. Are associated to rifampicin resistance if tested on solid media, may test sensitive when tested in MGIT. Associated to poor clinical outcome should be interpreted as conferring resistance and rifampicin should not be counted as a fully active drug in the therapeutic regimen. S522 L, H526L, H526A, H526C, D516F, D516V: those mutations have been associated to rifampicin resistance and rifabutin sensitivity. This is still a disputed issue and more data on mic distribution for rifabutin are needed
Ethambutol	<i>embB</i>	M306V	M306L, M306I, D354A, G406D, etc	M306V is the most frequent mutation associated with R to EMB.
				Not all mutations in <i>embB</i> are associated with EMB-R. Discrepant phenotypic/genotypic results are expected due to the CC used for in vitro testing

(continued)

Table 12.5 (continued)

Antimicrobial agent	Gene	Common mutations	Less common mutations	Expected phenotype
Pyrazinamide	<i>pncA</i>	No predominant mutations		Pyrazinamide monoresistance is associated to <i>M.bovis</i> and <i>M.bovis</i> /BCG due to the presence of a characteristic mutation in position 57. For all other cases phenotypic resistance to pyrazinamide in the absence of mutations should be interpreted as false resistance. <i>pncA</i> mutations are widely distributed throughout the gene and its promoter. Some mutations such as E37V, D110G, V163A, A170V and V180I, are not associated with PZA-R
	<i>panD</i>		I49V, I115T	Few data to support the role of <i>panD</i> as main determinant for PZA resistance. It is causing resistance in <i>M. canettii</i>
Quinolones	<i>gyrA</i>	D94G	D94Y, D94H, D94A, D94N, S91P; G88A, mutations outside hot spot	D94G causes resistance to all fluoroquinolones (including moxifloxacin and gatifloxacin) in the presence of this mutation fluoroquinolone treatment is not recommended or if performed should be condered potentially not effective despite results of “in vitro” phenotypic testing
		A90V		A90V is associated resistance to levofloxacin and to lower level resistance to moxifloxacin and gatifloxacin
Amikacin	<i>rrs</i>	1401A/G	1484G/T	1401A/G is the most frequent mutation; confers resistance to AMK and all second line injectables 1484G/T may be associated with R to AMK.
	<i>eis</i>		-14C/T	may confer very low level resistance
Capreomycin	<i>rrs</i>	1401A/G	1402C/T, 1484G/T	1401A/G is the most common mutation; Usually associated with R to CAP. 1402C/T and 1484G/T mutations may also be associated with R to CAP.
		<i>tlyA</i>	No predominant mutations	Mutations are widely distributed throughout the gene. Not all mutations are associated with R to CAP. role of the different mutations is still disputed
Kanamycin	<i>rrs</i>	1401A/G,	1402C/T, 1484G/T	1401A/G is the most common mutation and associated with high level R to KAN. 1402C/T may be associated with low-level R to KAN.
	<i>eis promoter</i>	-10G/A		Confer KAN-resistance, short MDR regimen with kanamycin cannot be used for treatment. May induces increased mic to Amikacin. Capreomycin could still be effective
		-12C/T		
		-14C/T		
		-37G/T		
				-12C/T may confer low level R to KAN.

(continued)

Table 12.5 (continued)

Antimicrobial agent	Gene	Common mutations	Less common mutations	Expected phenotype
Bedaquiline	<i>atpE</i>	D28N, A63V		Mutations in C ring of the ATP synthase may be associated with BDQ resistance.
	<i>mmpR</i>	No predominant mutations		A new publication indicated mutations in <i>mmpR</i> may be associated with BDQ-R.
Delamanid	<i>fbiA</i> (Rv3261), <i>fbiB</i> (Rv3262), <i>fbiC</i> (Rv1173), <i>fgd1</i> (Rv0407)			Mutations in genes involved in coenzyme F420 biosynthesis and metabolism has been proposed as possible mechanisms of resistance to DLM (Choi KP <i>et al.</i> , <i>J. Bacteriol.</i> 2002) <i>several mutations have been observed but data correlating to DR are not yet available</i>
	<i>ddn</i>			<i>Stop codons in the ddn have been associated to high level resistance</i>

could explain the discrepancies observed between phenotypic and genotypic results. With the increasing number of genomic loci identified by WGS as linked to resistance, the value of this approach will increase in particular for use in laboratory routine (Drobniewski *et al.* 2015; Pankhurst *et al.* 2016). Recent studies underlined that over 100 genetic regions are involved in the drug resistance pathways and that mutations found within these regions could play relevant roles. WGS therefore appears the most suitable approach for a comprehensive analysis, given an appropriate validation of all the mutations by MIC and allelic exchange experiments, and considering the correlation with clinical outcomes (Zhang and Yew 2015). At the moment, WGS can be used to rapidly identify the known conferring-resistance mutations and, consequently, to guide individualized treatment decisions, even supporting for some drugs the phenotypic DST results, due to the reliability issues of the latter (Koser 2013). Among the advantages of WGS over the molecular tools currently recommended by the WHO, there is the possibility to provide information on the specific nucleotide substitutions that confer different levels of phenotypic resistance (e.g. mutations affecting codons 90 and 94 in *gyrA*) and the analysis of large genomic regions not limited to hotspot fragments (e.g. *pncA* complete coding and promoter sequencing; mutations outside the *rpoB* RRDR and *gyrA-gyrB* QRDR). WGS can also provide information to support

conventional contact tracing for epidemiological studies, given its high discriminatory power in determining phylogenetic lineages (see Chap. 4), and in tracking the circulating strains and their relatedness (Drobniewski *et al.* 2015; WHO/UNITAID 2015; Witney *et al.* 2015). Thus, it may be possible to diagnose drug resistance and monitor transmission events at the same moment, with considerable impact on public health strategies (Arinaminpathy 2015). WGS platforms have been already adopted in many TB supranational and national reference laboratories, as well as in research laboratories: several groups are working to reduce the complexity of such technologies, from the hardware to the analysis part, with the final aim to make this technology accessible to all (Chap. 3). Already, several Countries are moving towards a centralized genomic approach for detection of sensitivity at least to first line antitubercular drugs. In addition WGS provides detailed information on the prevalence of strains and drug resistance patterns in the different settings, thus helping the strategies adopted by TB control programs at local and national levels (WHO/UNITAID 2015; Zignol *et al.* 2016). The cost of WGS varies depending on the technologies and numbers of sample analysed, and it has now probably reached the price range of the other tests performed in the hospital laboratories. The cost benefit depends also on the time needed to provide results, with a reduction of around 4 weeks compared to phenotypic

DST, avoiding also the use of ineffective and expensive drugs and hospital isolation sectors for long period of time (Drobniewski et al. 2015; Witney et al. 2015). Despite the great opportunity to provide a comprehensive analysis of MTB primary cultures including species identification, simultaneous determination of resistance to all the anti-TB drugs through the interrogation of the known molecular targets, and genotyping and phylogenetic investigation to track the transmission events, the use of the generated information is challenging in decentralized facilities due to the computational capacity and bioinformatics skills required, and to the lack of standardized reference, analysis pipelines, and interpretation tools (Schito and Dolinger 2015).

Moving from culture-based WGS to direct analysis from clinical samples with fully automated platforms could be the next step to make this approach suitable for high burden settings. Commercial tests based on NGS of specific targets are under development and will be available in a near future.

12.6 Clinical Considerations

Moving into the era of “personalized medicine” requires an appropriate and accurate classification of the bacterial strains causing TB for both the sensitivity patterns and the genotype. Treatment of TB and of drug-resistant TB in particular is still very long and associated with toxicity and irreversible side effects. Treatment initiation in the absence of data on the susceptibility of the strain to the drugs selected should be avoided whenever possible. Each patient deserves a reliable drug sensitivity test done under the best conditions in a quality assured laboratory.

The introduction of additional therapeutic options, ranging from the adoption of the short MDR regimen to the introduction of new or repurposed drugs, requires a “triaging” of the patient with MDR-TB in the shortest possible time, it is clear that only molecular tools can respond to this need.

In the past few years DST for *M. tuberculosis* has evolved from a mostly “home made” test per-

formed in few laboratories with doubtful results with turnaround time of months to a much needed high-tech test. The promise of WGS is now the “all in one” approach, with a prediction of the resistance pattern associated to epidemiological and genotypic information from clinical samples.

Although we recognize that rapid molecular tests are still unable to predict sensitivity or resistance in 100% of cases, they are still able to guide therapy in the high majority of cases allowing not starting or early discontinuation of potentially toxic therapy in cases in which resistance can be predicted.

It is becoming clear that the concept of “one gold standard method” for testing *M. tuberculosis* susceptibility to antibiotics is challenged by the fact that the different tests are providing results that at first may appear conflicting. This is causing confusion among clinicians and reluctance in modifying therapy. We need to accept that each drug may have a different testing standard and that for some drug the genotypic results will overrule the phenotype.

In some cases the use of MIC will provide substantial information to decide on the discontinuation of a therapy.

In the future, the same investment should be made in training clinician in the interpretation of molecular tests and MIC-based test, that we have devoted to train microbiologists in the use of molecular tests in order to translate into clinical action the information that the technology will allow to collect.

References

- Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, Manavathu EK, Lerner SA (1998) Mechanism of resistance to amikacin and kanamycin in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 42(5):1295–1297
- Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E (2016) Mutations in *pepQ* confer low-level resistance to bedaquiline and clofazimine in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 60(8):4590–4599
- Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van Ingen J, Cambau E (2016) Consensus numbering sys-

- tem for the rifampicin resistance-associated *rpoB* gene mutations in pathogenic mycobacteria. *Clin Microbiol Infect* 23:167–172. pii: S1198-743X(16)30393-7
- Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V (2005) A diarylquinoline drug active on the ATP synthase of *Mycobacterium tuberculosis*. *Science* 307(5707):223–227
- Andries K, Villedas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A (2014) Acquired resistance of *Mycobacterium tuberculosis* to bedaquiline. *PLoS One* 9(7):e102135
- Arentz M, Sorensen B, Horne DJ, Walson JL (2013) Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis. *PLoS One* 8(10):e76533
- Arinaminpathy N, Dowdy D (2015) Understanding the incremental value of novel diagnostic tests for tuberculosis. *Nature* 528(7580):S60–S67. <https://doi.org/10.1038/nature16045>
- Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM (2006) Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of *Mycobacterium tuberculosis*: functional analysis of mutant enzymes. *Antimicrob Agents Chemother* 50(1):104–112
- Avalos E, Catanzaro D, Catanzaro A, Ganiats T, Brodine S, Alcaraz J, Rodwell T (2015) Frequency and geographic distribution of *gyrA* and *gyrB* mutations associated with fluoroquinolone resistance in clinical *Mycobacterium tuberculosis* isolates: a systematic review. *PLoS One* 10(3):e0120470
- Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr (1994) *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* 263(5144):227–230
- Banerjee A, Sugantino M, Sacchetti JC, Jacobs WR Jr (1998) The *mabA* gene from the *inhA* operon of *Mycobacterium tuberculosis* encodes a 3-ketoacyl reductase that fails to confer isoniazid resistance. *Microbiology* 144(Pt 10):2697–2704
- Baquero F (2001) Low-level antibacterial resistance: a gateway to clinical resistance. *Drug Resist Updat* 4(2):93–105
- Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S (2012) *rplC* T460C identified as a dominant mutation in linezolid-resistant *Mycobacterium tuberculosis* strains. *Antimicrob Agents Chemother* 56(5):2743–2745
- Berrada ZL, Lin SG, Rodwell TC, Nguyen D, Schecter GF, Pham L, Janda JM, Elmarachli W, Catanzaro A, Desmond E (2016) Rifabutin and rifampin resistance levels and associated *rpoB* mutations in clinical isolates of *Mycobacterium tuberculosis* complex. *Diagn Microbiol Infect Dis* 85:177–181. pii: S0732-8893(16)30001-3
- Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC (2015) Acquired resistance to Bedaquiline and Delamanid in therapy for tuberculosis. *N Engl J Med* 373(20):1986–1988
- Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RL, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med* 167(4):603–662
- Bodmer T, Zürcher G, Imboden P, Telenti A (1995) Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant *Mycobacterium tuberculosis*. *J Antimicrob Chemother* 35(2):345–348
- Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD (2010) Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 363(11):1005–1015
- Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, Earle S, Pankhurst LJ, Anson L, de Cesare M, Piazza P, Votintseva AA, Golubchik T, Wilson DJ, Wyllie DH, Diel R, Niemann S, Feuerriegel S, Kohl TA, Ismail N, Omar SV, Smith EG, Buck D, McVean G, Walker AS, Peto TE, Crook DW, Iqbal Z (2015) Rapid antibiotic-resistance predictions from genome sequence data for *Staphylococcus aureus* and *Mycobacterium tuberculosis*. *Nat Commun* 6:10063
- Brandis G, Wrande M, Liljas L, Hughes D (2012) Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. *Mol Microbiol* 85(1):142–151
- Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, Aubry A, French National Reference Center for Mycobacteria (Members of the French National Reference Center for Mycobacteria: Christine Bernard, Emmanuelle Cambau, Vincent Jarlier, Faiza Mougari, Laurent Raskine, Jérôme Robert) (2016) Performance of the New V2.0 of the GenoType MTB-DRsl test for the detection of resistance to second-line drugs in multidrug-resistant *Mycobacterium tuberculosis* complex strains. *J Clin Microbiol* 54:1573–1580. pii: JCM.00051-16. [Epub ahead of print]
- Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE (2011) Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of mycobacterium tuberculosis. *Antimicrob Agents Chemother* 55(5):2032–2041

- Canetti G, Froman S, Grosset J, Haudoroy P, Langerová M, Mahler HT, Meissner G, Mitchison DA, Sula L (1963) Mycobacteria: laboratory methods for testing drug susceptibility and resistance. *Bull WHO* 29:565–578
- Canetti G, Fox W, Khomenco A, Mahler HT, Menon NK, Mitchison DA, Rist N, Šmelev NA (1969) Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. *Bull WHO* 41:21–43
- Caws M, Drobniewski FA (2001) Molecular techniques in the diagnosis of *Mycobacterium tuberculosis* and the detection of drug resistance. *Ann N Y Acad Sci* 953:138–145
- Chakravorty S, Simmonds AM, Parmar H, Cao Y et al (2017) The New Xpert MTB/RIF Ultra: Improving Detection of *Mycobacterium tuberculosis* and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. *mBio* 8(4):e00812–e00817
- Chien JY, Chiu WY, Chien ST, Chiang CJ, CJ Y, Hsueh PR (2016) Mutations in *gyrA* and *gyrB* among fluoroquinolone- and multidrug-resistant mycobacterium tuberculosis isolates. *Antimicrob Agents Chemother* 60(4):2090–2096
- Choi KP, Bair TB, Bae YM, Daniels L (2001) Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for *fbiA* and *fbiB* in coenzyme F(420) biosynthesis by *Mycobacterium Bovis* BCG. *J Bacteriol* 183(24):7058–7066
- Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E, Van Deun A, Rigouts L (2016) Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in mycobacterium tuberculosis. *J Antimicrob Chemother* 71(5):1233–1240
- Coker RJ (2004) Review: multidrug-resistant tuberculosis: public health challenges. *Tropical Med Int Health* 9(1):25–40
- Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, Mallard K (2015) Nair M4, Miranda a, Alves a, Perdigão J, Viveiros M, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, pain a, Clark TG. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. *Genome Med* 7(1):51
- Collins LA, Franzblau SG (1997) Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium*. *Antimicrob Agents Chemother* 41:1004–1009
- Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S (2011) Whole-genome sequencing of rifampicin-resistant mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. *Nat Genet* 44(1):106–110
- da Silva PE, Von Groll A, Martin A, Palomino JC (2011) Efflux as a mechanism for drug resistance in mycobacterium tuberculosis. *FEMS Immunol Med Microbiol* 63(1):1–9
- Dartois V, Barry CE 3rd (2013) A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. *Bioorg Med Chem Lett* 23(17):4741–4750
- Dartois V, Saito K, Warriar T, Nathan C (2016) New evidence for the complexity of the population structure of mycobacterium tuberculosis increases the diagnostic and biologic challenges. *Am J Respir Crit Care Med* 194(12):1448–1451
- De Rossi E, Afnsa JA, Riccardi G (2006) Role of mycobacterial efflux transporters in drug resistance: an unresolved question. *FEMS Microbiol Rev* 30(1):36–52
- de Vos M, Müller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC (2013) Putative compensatory mutations in the *rpoC* gene of rifampin-resistant mycobacterium tuberculosis are associated with ongoing transmission. *Antimicrob Agents Chemother* 57(2):827–832
- Denkinger CM, Schumacher SG, Boehme CC, N D, Pai M, Steingart KR (2014) Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 44(2):435–446
- Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD (2015) Target product profile of a molecular drug-susceptibility test for use in microscopy centers. *J Infect Dis* 211(Suppl 2):S39–S49
- Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE (2008) Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. *Proc Natl Acad Sci U S A* 105(32):11293–11298
- Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, Townsend C, Sivaramakrishnan A, Green N, Jit M, Lipman M, Lord J, White PJ, Abubakar I (2015) Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. *Health Technol Assess* 19(34):1–188. vii–viii
- Emmart EW (1945) The tuberculostatic action of streptomycin and streptomycin with special reference to the action of streptomycin on the chorioallantoic membrane of the chick embryo. *Public Health Rep* 60:1415–1421
- Escribano I, Rodríguez JC, Llorca B, García-Pachon E, Ruiz M, Royo G (2007) Importance of the efflux pump systems in the resistance of *Mycobacterium tuberculosis* to fluoroquinolones and linezolid. *Chemotherapy* 53(6):397–401
- Farhat MR, Mitnick CD, Franke MF, Kaur D, Sloutsky A, Murray M, Jacobson KR (2015) Concordance of *Mycobacterium tuberculosis* fluoroquinolone resistance testing: implications for treatment. *Int J Tuberc Lung Dis* 19(3):339–341
- Farhat MR, Jacobson KR, Franke MF, Kaur D, Sloutsky A, Mitnick CD, Murray M (2016a) Gyrase mutations are associated with variable levels of fluoroquinolone

- resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 54(3):727–733
- Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M (2016b) Genetic determinants of drug resistance in *Mycobacterium tuberculosis* and their diagnostic value. *Am J Respir Crit Care Med* 194(5):621–630
- Feuerriegel S, Köser CU, Baù D, Rüsç-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, Niemann S (2011) Impact of *Fgd1* and *ddn* diversity in *Mycobacterium tuberculosis* complex on in vitro susceptibility to PA-824. *Antimicrob Agents Chemother* 55(12):5718–5722
- Feuerriegel S, Köser CU, Niemann S (2014) Phylogenetic polymorphisms in antibiotic resistance genes of the *Mycobacterium tuberculosis* complex. *J Antimicrob Chemother* 69(5):1205–1210
- Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, Cabibbe AM, Niemann S, Fellenberg K (2015) PhyResSE: a web tool delineating *Mycobacterium tuberculosis* antibiotic resistance and lineage from whole-genome sequencing data. *J Clin Microbiol* 53(6):1908–1914
- Flandrois JP, Lina G, Dumitrescu O (2014) MUBII-TB-DB: a database of mutations associated with antibiotic resistance in *Mycobacterium tuberculosis*. *BMC Bioinformatics* 15:107
- García de Viedma D (2003) Rapid detection of resistance in *Mycobacterium tuberculosis*: a review discussing molecular approaches. *Clin Microbiol Infect* 9(5):349–359
- Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC (2012) Evaluation of genetic mutations associated with *Mycobacterium tuberculosis* resistance to amikacin, kanamycin and capreomycin: a systematic review. *PLoS One* 7(3):e33275
- Gilchrist CA, Turner SD, Riley MF, Petri WA Jr, Hewlett EL (2015) Whole-genome sequencing in outbreak analysis. *Clin Microbiol Rev* 28(3):541–563
- Gillespie SH (2002) Evolution of drug resistance in *Mycobacterium tuberculosis*: clinical and molecular perspective. *Antimicrob Agents Chemother* 46(2):267–274
- Gilpin C, Korobitsyn A, Weyer K (2016) Current tools available for the diagnosis of drug-resistant tuberculosis. *Ther Adv Infectious Dis* 3:1–7
- Goldstein BP (2014) Resistance to rifampicin: a review. *J Antibiot (Tokyo)* 67(9):625–630
- Guernsey BG, Alexander MR (1978) Tuberculosis: review of treatment failure, relapse and drug resistance. *Am J Hosp Pharm* 35(6):690–698
- Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL (2012) Evaluation of the Sensititre MycoTB plate for susceptibility testing of the *Mycobacterium tuberculosis* complex against first- and second-line agents. *J Clin Microbiol* 50(11):3732–3734
- Harms A, Maisonneuve E, Gerdes K (2016) Mechanisms of bacterial persistence during stress and antibiotic exposure. *Science* 354(6318):aaf4268
- Hartkoom RC, Uplekar S, Cole ST (2014) Cross-resistance between clofazimine and bedaquiline through upregulation of *MmpL5* in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 58(5):2979–2981
- He L, Wang X, Cui P, Jin J, Chen J, Zhang W, Zhang Y (2015) *ubiA* (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)* 95(2):149–154
- Hillemann D, Rüsç-Gerdes S, Richter E (2008) In vitro selected linezolid-resistant *Mycobacterium tuberculosis* mutants. *Antimicrob Agents Chemother* 52(2):800–801
- Hoshide M, Qian L, Rodrigues C, Warren R, Victor T, Evasco HB 2nd, Tupasi T, Crudu V, Douglas JT (2014) Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of *Mycobacterium tuberculosis*. *J Clin Microbiol* 52(5):1322–1329
- Huh HJ, Jeong BH, Jeon K, Koh WJ, Ki CS, Lee NY (2014) Performance evaluation of the Xpert MTB/RIF assay according to its clinical application. *BMC Infect Dis* 14:589
- Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI (2010) Rates and mechanisms of resistance development in *Mycobacterium tuberculosis* to a novel diarylquinoline ATP synthase inhibitor. *Antimicrob Agents Chemother* 54(3):1022–1028
- Imperiale BR, Di Giulio AB, Adrián Cataldi A, Morcillo NS (2014) Evaluation of *Mycobacterium tuberculosis* cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. *J Antibiot (Tokyo)* 67(11):749–754
- Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C (2014) Profiling of *rpoB* mutations and MICs for rifampin and rifabutin in *Mycobacterium tuberculosis*. *J Clin Microbiol* 52(6):2157–2162
- Jiang GL, Chen X, Song Y, Zhao Y, Huang H, Kam KM (2013) First proficiency testing of second-line anti-tuberculosis drug susceptibility testing in 12 provinces of China. *Int J Tuberc Lung Dis* 17(11):1491–1494
- Jo KW, Lee SD, Kim WS, Kim DS, Shim TS (2014) Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 18(1):39–43
- Johansen SK, Maus CE, Plikaytis BB, Douthwaite S (2006) Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs. *Mol Cell* 23(2):173–182
- Jones D, Metzger HJ, Schatz A, Waksman SA (1944) Control of gram-negative bacteria in experimental animals by streptomycin. *Science* 100(2588):103–105
- Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY (2006) Stepwise decrease in moxifloxacin

- susceptibility amongst clinical isolates of multidrug-resistant *Mycobacterium tuberculosis*: correlation with ofloxacin susceptibility. *Microb Drug Resist* 12(1): 7–11
- Kampli P, Ajbani K, Sadani M, Nikam C, Shetty A, Udawadia Z, Rodwell TC, Catanzaro A, Rodrigues C (2015) Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with *gyrA* mutations using the genotype MTBDRsl assay. *Tuberculosis (Edinb)* 95(2):137–141
- Kampli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udawadia Z, Georghiou SB, Rodwell TC, Catanzaro A, Rodrigues C (2016) Correlating *rrs* and *eis* promoter mutations in clinical isolates of *Mycobacterium tuberculosis* with phenotypic susceptibility levels to the second-line injectables. *Int J Mycobacteriol* 5(1):1–6
- Kelley CL, Rouse DA, Morris SL (1997) Analysis of *ahpC* gene mutations in isoniazid-resistant clinical isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 41(9):2057–2058
- Kent PT, Kubica GP (1985) Antituberculosis chemotherapy and drug susceptibility testing. In: Kent PT, Kubica GP (eds) *Public health mycobacteriology. A guide for the level III laboratory*. U.S. Department of Health and Human Services, Atlanta, pp 159–184
- Kik SV, Denkinger CM, Casenghi M, Vadnais C, Pai M (2014) Tuberculosis diagnostics: which target product profiles should be prioritised? *Eur Respir J* 44(2):537–540
- Kim SJ (2005) Drug-susceptibility testing in tuberculosis: methods and reliability of results. *Eur Respir J* 25(3):564–569
- Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ (2013) Whole-genome sequencing for rapid susceptibility testing of *M. tuberculosis*. *N Engl J Med* 369(3):290–292. <https://doi.org/10.1056/NEJMc1215305>. No abstract available
- Kronvall G (2010) Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints. *J Clin Microbiol* 48(12):4445–4452
- Lee AS, Teo AS, Wong SY (2001) Novel mutations in *ndh* in isoniazid-resistant *Mycobacterium tuberculosis* isolates. *Antimicrob Agents Chemother* 45(7):2157–2159
- Lemaitre N, Sougakoff W, Truffot-Pernot C, Jarlier V (1999) Characterization of new mutations in pyrazinamide-resistant strains of *Mycobacterium tuberculosis* and identification of conserved regions important for the catalytic activity of the pyrazinamidase *PncA*. *Antimicrob Agents Chemother* 43(7):1761–1763
- Ling DI, Zwerling AA, Pai M (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. *Eur Respir J* 32(5):1165–1174
- Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL, German S, Cho E, Lee JI, Cho SN, Kim CT, Alland D, Safi H (2016) Geographic differences in the contribution of *ubiA* mutations to high-level Ethambutol Resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. pii: AAC.03002-15. [Epub ahead of print]
- Lippincott CK, Miller MB, Van Rie A, Weber DJ, Sena AC, Stout JE (2015) The complexities of Xpert® MTB/RIF interpretation. *Int J Tuberc Lung Dis* 19(3):273–275
- Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC (2009) A balancing act: efflux/influx in mycobacterial drug resistance. *Antimicrob Agents Chemother* 53(8):3181–3189
- Madison B, Robinson-Dunn B, George I et al (2002) Multicenter evaluation of ethambutol susceptibility testing of *Mycobacterium tuberculosis* by agar proportion and radiometric methods. *J Clin Microbiol* 40:3976–3979
- Makafe GG, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire MM, Cai X, Liu T, Wang B, Pang W, Tan S, Zhang B, Yew WW, Lamichhane G, Guo J, Zhang T (2016) Role of the Cys154Arg substitution in ribosomal protein L3 in Oxazolidinone resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 60(5):3202–3206
- Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE (2012) New insights into fluoroquinolone resistance in *Mycobacterium tuberculosis*: functional genetic analysis of *gyrA* and *gyrB* mutations. *PLoS One* 7(6): e39754
- Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L, Dick T, Pang SS, Barry CE 3rd (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 103(2):431–436
- Martínez JL, Coque TM, Baquero F (2015) What is a resistance gene? Ranking risk in resistomes. *Nat Rev Microbiol* 13(2):116–123
- Marttila HJ, Soini H (2003) Molecular detection of resistance to antituberculous therapy. *Clin Lab Med* 23(4):823–841. v-vi
- Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M (2006) OPC-67683, a nitro-dihydro-imidazo-oxazole derivative with promising action against tuberculosis in vitro and in mice. *PLoS Med* 3(11):e466
- Maus CE, Plikaytis BB, Shinnick TM (2005) Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 49(8):3192–3197
- Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniowski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopec E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüscherger S, Niemann S, Cirillo DM (2014) *Mycobacterium tuberculosis* pyrazinamide resistance determinants: a multicenter study. *MBio* 5(5):e01819-14
- Miotto P, Cirillo DM, Migliori GB (2015) Drug resistance in *Mycobacterium tuberculosis*: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. *Chest* 147(4):1135–1143

- Moore DA, Mendoza D, Gilman RH, Evans CA, Hollm Delgado MG, Guerra J, Caviedes L, Vargas D, Ticona E, Ortiz J, Soto G, Serpa J (2004) Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings. *J.Clin.Microbiol.* 42:4432–4437
- Morgan M, Kalantri S, Flores L, Pai M (2005) A commercial line probe assay for the rapid detection of rifampicin resistance in *Mycobacterium tuberculosis*: a systematic review and meta-analysis. *BMC Infect Dis* 5:62
- Nathan C (2012) Fresh approaches to anti-infective therapies. *Sci Transl Med* 4(140):140sr2
- Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Vally Omar S, Sikhondze W, Havumaki J, Valli E, Boehme C, Denkinge CM (2016) A Multi-Center Non-inferiority Evaluation of Hain GenoType MTBDRplus Version 2 and Nipro NTM+MDR-TB lineprobe assays for the diagnosis of Rifampin and Isoniazid Resistance. *J Clin Microbiol.* pii: JCM.00251-16. [Epub ahead of print]
- Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM (2013) Analysis of mutations in the *gyrA* and *gyrB* genes and their association with the resistance of *Mycobacterium tuberculosis* to levofloxacin, moxifloxacin and gatifloxacin. *J Med Microbiol* 62(Pt 1):108–113
- Okamoto S, Tamaru A, Nakajima C, Nishimura K, Tanaka Y, Tokuyama S, Suzuki Y, Ochi K (2007) Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. *Mol Microbiol* 63(4):1096–1106
- Pandey B, Grover S, Tyagi C, Goyal S, Jamal S, Singh A, Kaur J, Grover A (2016) Molecular principles behind pyrazinamide resistance due to mutations in *panD* gene in *Mycobacterium tuberculosis*. *Gene* 581(1):31–42
- Pankhurst LJ, del Ojo Elias C, Votintseva AA, Walker TM, Cole K, Davies J, Fermont JM, Gascoyne-Binzi DM, Kohl T, Kong C, Lemaitre N, Niemann S, Paul J, Rogers TR, Roycroft E, Smith G, Supply P, Tang P, Wilcox MH, Wordsworth S, Wyllie D, Xu L, Crook W, Rapid DW (2016) Comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. *Lancet Respir Med* 4(1):49–58. [https://doi.org/10.1016/S2213-2600\(15\)00466-X](https://doi.org/10.1016/S2213-2600(15)00466-X)
- Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J (2011) Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. *Clin Microbiol Rev* 24(2):314–350
- Patel RJ, Fries JW, Piessens WF, Wirth DF (1990) Sequence analysis and amplification by polymerase chain reaction of a cloned DNA fragment for identification of *Mycobacterium tuberculosis*. *J Clin Microbiol* 28(3):513–518
- Piersimoni C, Mastazzolu A, Giannoni F, Bornigia S, Gherardi G, Fattorini L (2013) Prevention of false resistance results obtained in testing the susceptibility of *Mycobacterium tuberculosis* to pyrazinamide with the Bactec MGIT 960 system using a reduced inoculum. *J Clin Microbiol* 51(1):291–294
- Punina NV, Makridakis NM, Remnev MA, Topunov AF (2015) Whole-genome sequencing targets drug-resistant bacterial infections. *Hum Genomics* 9:19
- Ramaswamy S, Musser JM (1998) Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuber Lung Dis* 79(1):3–29
- Ramirez-Busby SM, Valafar F (2015) Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in *Mycobacterium tuberculosis* clinical isolates. *Antimicrob Agents Chemother* 59(9):5267–5277
- Reeves AZ, Campbell PJ, Sultana R, Malik S, Murray M, Plikaytis BB, Shinnick TM, Posey JE (2013) Aminoglycoside cross-resistance in *Mycobacterium tuberculosis* due to mutations in the 5' untranslated region of *whiB7*. *Antimicrob Agents Chemother* 57(4):1857–1865
- Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A (2013) Rifampin resistance missed in automated liquid culture system for *Mycobacterium tuberculosis* isolates with specific *rpoB* mutations. *J Clin Microbiol* 51(8):2641–2645
- Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A (2016) Specific *gyrA* gene mutations predict poor treatment outcome in MDR-TB. *J Antimicrob Chemother* 71(2):314–323
- Rueda J, Realpe T, Mejia GI, Zapata E, Roza JC, Ferro BE, Robledo J (2015) Genotypic analysis of genes associated with independent resistance and cross-resistance to Isoniazid and Ethionamide in *Mycobacterium tuberculosis* clinical isolates. *Antimicrob Agents Chemother* 59(12):7805–7810
- Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S (2014) Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant *Mycobacterium tuberculosis*. *J Clin Microbiol* 52(6):1846–1852. <https://doi.org/10.1128/JCM.03005-13>. Epub 2014 Mar 19
- Rüsch-Gerdes S, Domehl C, Nardi G, Gismondo MR, Welscher HM, Pfyffer GE (1999) Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of *Mycobacterium tuberculosis* to first-line drugs. *J Clin Microbiol* 37(1):45–48
- Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, McNeil M, Peterson SN, Chatterjee D, Fleischmann R, Alland D (2013) Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl- β -D-arabinose biosynthetic and utilization pathway genes. *Nat Genet* 45(10):1190–1197
- Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, Bonnet M, Niemann S (2015) Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. *N Engl J Med* 372(12):1181–1182

- Saraav I, Pandey K, Misra R, Singh S, Sharma M, Sharma S (2017) Characterization of MymA protein as a flavin-containing monooxygenase and as a target of isoniazid. *Chem Biol Drug Des* 89(1):152–160
- Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Utpatel C, Merker M, Trovato A, Hofmann-Thiel S, Hoffmann H, Cirillo DM (2016) Delamanid susceptibility testing of *Mycobacterium tuberculosis* using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system. *J Antimicrob Chemother* 71(6):1532–1539. <https://doi.org/10.1093/jac/dkw044>
- Schito M, Dolinger DL (2015) A collaborative approach for “ReSeq-ing” *Mycobacterium tuberculosis* drug resistance: convergence for drug and diagnostic developers. *EBioMedicine* 2(10):1262–1265
- Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S (2012) New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. *Antimicrob Agents Chemother* 56(5):2326–2334
- Seifert M, Catanzaro D, Catanzaro A, Rodwell TC (2015) Genetic mutations associated with isoniazid resistance in *Mycobacterium tuberculosis*: a systematic review. *PLoS One* 10(3):e0119628
- Seifert M, Georghiou SB, Catanzaro D, Rodrigues C, Cruu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC (2016) MTBDRplus and MTBDRsl assays: absence of wild-type probe hybridization and implications for detection of drug-resistant tuberculosis. *J Clin Microbiol* 54(4):912–918
- Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, Singh M (2015) Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of *Mycobacterium tuberculosis* and their relationship with MIC of ofloxacin. *J Antibiot (Tokyo)* 68(1):63–66
- Sintchenko V, Chew WK, Jelfs PJ, Gilbert GL (1999) Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant *Mycobacterium tuberculosis* strains isolated in Australia. *Pathology* 31(3):257–260
- Slayden RA, Barry CE 3rd (2000) The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. *Microbes Infect* 2(6):659–669
- Smith DG, Waskman SA (1947) Tuberculostatic and tuberculocidal action of streptomycin. *J Bacteriol* 54(1):67
- Smith T, Wolff KA, Nguyen L (2013) Molecular biology of drug resistance in *Mycobacterium tuberculosis*. *Curr Top Microbiol Immunol* 374:53–80
- Somoskovi A, Salfinger M (2015) The race is on to shorten the turnaround time for diagnosis of multidrug-resistant tuberculosis. *J Clin Microbiol* 53(12):3715–3718
- Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreiswirth BN, Musser JM (1996) Characterization of rpsL and rrs mutations in streptomycin-resistant *Mycobacterium tuberculosis* isolates from diverse geographic localities. *Antimicrob Agents Chemother* 40(4):1024–1026
- Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM (1997) Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 41(3):600–606
- Starks AM, Avilés E, Cirillo DM, Denkinger CM, Dolinger DL, Emerson C, Gallarda J, Hanna D, Kim PS, Liwski R, Miotto P, Schito M, Zignol M (2015) Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. *Clin Infect Dis* 61(Suppl 3):S141–S146
- Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S (2014) KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. *BMC Genomics* 15:881
- Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N (2014) Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev* 1:CD009593
- Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WRA (2000) Small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature* 405(6789):962–966
- Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM (2015) Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. *J Clin Microbiol* 53(9):2961–2969
- Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L, Schopfer K, Bodmer T (1993) Detection of rifampicin-resistance mutations in *Mycobacterium tuberculosis*. *Lancet* 341(8846):647–650
- Telenti A, Philipp WJ, Sreevatsan S, Bernasconi C, Stockbauer KE, Wiele B, Musser JM, Jacobs WR Jr (1997) The emb operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol. *Nat Med* 3(5):567–570
- Theron G, Peter J, Richardson M, Barnard M, Donegan S, Warren R, Steingart KR, Dheda K (2014) The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. *Cochrane Database Syst Rev* 10:CD010705
- Torrea G, Coeck N, Desmaretz C, Van De Parre T, Van Poucke T, Lounis N, de Jong BC, Rigouts L (2015) Bedaquiline susceptibility testing of *Mycobacterium tuberculosis* in an automated liquid culture system. *J Antimicrob Chemother* 70(8):2300–2305
- Tortoli E, Benedetti M, Fontanelli A, Simonetti MT (2002) Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of *Mycobacterium tuberculosis* to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method

- and the agar plate method of proportion. *J Clin Microbiol* 40:607–610
- Uys PW, Warren R, van Helden PD, Murray M, Victor TC (2009) Potential of rapid diagnosis for controlling drug-susceptible and drug-resistant tuberculosis in communities where *Mycobacterium tuberculosis* infections are highly prevalent. *J Clin Microbiol* 47(5):1484–1490
- Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, de Jong BC (2015) Disputed *rpoB* mutations can frequently cause important rifampicin resistance among new tuberculosis patients. *Int J Tuberc Lung Dis* 19(2):185–190
- van Doorn HR, Claas EC, Templeton KE, van der Zanden AG, te Koppele Vije A, de Jong MD, Dankert J, Kuijper EJ (2003) Detection of a point mutation associated with high-level isoniazid resistance in *Mycobacterium tuberculosis* by using real-time PCR technology with 3'-minor groove binder-DNA probes. *J Clin Microbiol* 41(10):4630–4635
- Vilch e C, Weisbrod TR, Chen B, Kremer L, Hazb n MH, Wang F, Alland D, Sacchettini JC, Jacobs WR Jr (2005) Altered NADH/NAD⁺ ratio mediates core-sistance to isoniazid and ethionamide in mycobacteria. *Antimicrob Agents Chemother* 49(2):708–720
- Wakamoto Y, Dhar N, Chait R, Schneider K, Signorino-Gelo F, Leibler S, McKinney JD (2013) Dynamic persistence of antibiotic-stressed mycobacteria. *Science* 339(6115):91–95
- Walker T, Kohl T, Omar S, Hedge J, Del Ojo E, Bradley P, Iqbal Z, Feuerrigel S, Niehaus K, Wilson D, Clifton D, Kapatai G, Ip C, Bowden C, Drobniwski F, Allix-B guez C, Gaudin C, Parkhill J, Diel R, Supply P, Crook D, Smith G, Walker S, Ismail N, Niemann S, Peto T (2015) Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: a retrospective cohort study. *The Lancet Infectious Diseases* 15:1193. [https://doi.org/10.1016/S1473-3099\(15\)00062-6](https://doi.org/10.1016/S1473-3099(15)00062-6)
- Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M (2013) Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. *Lancet Infect Dis* 13(5):449–458
- Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, van Helden PD, van Rie A (2015) A global perspective on pyrazinamide resistance: systematic review and meta-analysis. *PLoS One* 10(7):e0133869
- Willby M, Sikes RD, Malik S, Metchock B, Posey JE (2015) Correlation between *GyrA* substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 59(9):5427–5434
- Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA (2012) An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in *Mycobacterium tuberculosis*. *Diagn Microbiol Infect Dis* 74(2):207–209. <https://doi.org/10.1016/j.diagmicrobio.2012.06.013>. Epub 2012 Jul 20
- Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, Pond MJ, Pope CF, Planche TD, Stoker NG, Cosgrove CA, Butcher PD, Harrison TS, Hinds J (2015) Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. *J Clin Microbiol* 53(5):1473–1483
- Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HI, Barry CE 3rd (2011) Mutations in *gidB* confer low-level streptomycin resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 55(6):2515–2522
- World Health Organization (2004) Anti-tuberculosis drug resistance in the world, Third global report. WHO, Geneva. ISBN 92 4 156285 4. WHO/HTM/TB/2004.343
- World Health Organization (2008) Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB), Expert group report. WHO, Geneva
- World Health Organization (2012a) Tuberculosis laboratory biosafety manual. WHO, Geneva. ISBN 978 92 4 150463 8
- World Health Organization (2012b) Summary of outcomes from WHO expert group meeting on drug susceptibility testing. 4th annual GLI meeting 17 April 2012
- World Health Organization (2013) Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the: diagnosis of pulmonary and extrapulmonary TB in adults and children, Policy update. WHO, Geneva. ISBN: 978 92 4 150633 5. WHO/HTM/TB/2013.16
- World Health Organization, UNITAID (2015) Tuberculosis. Diagnostics technology and market landscape, 4th ed. Geneva
- World Health Organization (2016) The use of molecular line probe assays for the detection of resistance to second-line antituberculosis drugs, Policy guidance. WHO, Geneva. ISBN 978 92 4 150963 3
- World Health Organization, UNITAID (2015) Tuberculosis diagnostics technology and market landscape, 4th edn. WHO, Geneva
- Xu Y, Jia H, Huang H, Sun Z, Zhang Z (2015) Mutations found in *embCAB*, *emrB*, and *ubiA* genes of ethambutol-sensitive and -resistant *Mycobacterium tuberculosis* clinical isolates from China. *Biomed Res Int* 2015:951706
- Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, Nuermberger E, Lu Y (2017) Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. *Antimicrob Agents Chemother* 61(6):pii: e00239-17. doi:<https://doi.org/10.1128/AAC.00239-17>. Print 2017 Jun
- Yang J, Liu Y, Bi J, Cai Q, Liao X, Li W, Guo C, Zhang Q, Lin T, Zhao Y, Wang H, Liu J, Zhang X, Lin D (2015) Structural basis for targeting the ribosomal protein S1

- of *Mycobacterium tuberculosis* by pyrazinamide. *Mol Microbiol* 95(5):791–803
- Youmans GP, Williston EH et al (1946) Increase in resistance of tubercle bacilli to streptomycin; a preliminary report. *Proc Staff Meet Mayo Clin* 21:126
- Yu X, Ma YF, Jiang GL, Chen ST, Wang GR, Huang HR (2016) Sensititre[®] MYCOTB MIC plate for drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates. *Int J Tuberc Lung Dis* 20(3):329–334
- Zaunbrecher MA, Sikes RD Jr, Metchock B, Shinnick TM, Posey JE (2009) Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 106(47):20004–20009
- Zetola NM, Shin SS, Tumedji KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C (2014) Mixed *Mycobacterium tuberculosis* complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. *J Clin Microbiol* 52(7):2422–2429. <https://doi.org/10.1128/JCM.02489-13>. Epub 2014 Apr 30
- Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: a review. *Int J Tuberc Lung Dis* 7(1):6–21
- Zhang Y, Yew WW (2015) Mechanisms of drug resistance in *Mycobacterium tuberculosis*: update 2015. *Int J Tuberc Lung Dis* 19(11):1276–1289
- Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM et al (2016) Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. *Lancet Infect Dis* 16(10):1185–1192. [https://doi.org/10.1016/S1473-3099\(16\)30190-6](https://doi.org/10.1016/S1473-3099(16)30190-6)